Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Risks of specific hyposensitization treatment].

J Rakoski1

  • 1Dermatologische Klinik und Poliklinik der Technischen Universität München.

Zeitschrift Fur Hautkrankheiten
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgE-mediated type-I-allergy against red wine and grapes.

Allergy·2007
Same author

In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy.

Journal of investigational allergology & clinical immunology·2006
Same author

Quantitative patch and repeated open application testing in methyldibromo glutaronitrile-sensitive patients.

Contact dermatitis·2005
Same author

Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy.

Journal of investigational allergology & clinical immunology·2004
Same author

A short assessment of sublingual immunotherapy.

International archives of allergy and immunology·2001
Same author

[Allergen immunotherapy - a position paper of the German society for allergology and clinical immunology].

Pneumologie (Stuttgart, Germany)·2001

Specific hyposensitization is a successful treatment for IgE-mediated diseases, with a low risk of side effects. This report details fatal outcomes and proposes strategies to prevent serious complications during this immunotherapy.

Area of Science:

  • Immunology
  • Allergy and Clinical Immunology
  • Pharmacology

Context:

  • Specific hyposensitization is a treatment for IgE-mediated diseases.
  • Prospective studies indicate a 0.1-1% risk of side effects per injection.
  • Fatal outcomes have been reported in cases of specific hyposensitization.

Purpose:

  • To report on fatal outcomes associated with specific hyposensitization.
  • To suggest strategies for avoiding serious complications in allergen immunotherapy.
  • To highlight the importance of risk management in treating IgE-mediated conditions.

Summary:

  • Specific hyposensitization can be an effective treatment for diseases mediated by Immunoglobulin E (IgE).
  • While generally safe with a low risk of adverse events (0.1-1% per injection), fatal outcomes have occurred.

Related Experiment Videos

  • This study presents cases of fatal outcomes and proposes strategies to mitigate risks and prevent serious complications.

    • Impact:

    • Provides critical insights into the rare but severe risks of specific hyposensitization.
    • Offers practical strategies for clinicians to enhance patient safety during immunotherapy.
    • Contributes to the evidence base for optimizing allergen immunotherapy protocols and patient management.